Loading...
Counterpoint—The End Point: Less Is More
Improving the scientific and regulatory evaluation of therapies for metabolic disorders is a necessary ongoing process dependent on accruing knowledge and improving technology. The use of a composite primary efficacy outcome consisting of hemoglobin A1c (HbA1c) and hypoglycemia rates is alluring for...
Na minha lista:
| Hovedforfatter: | |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Diabetes Technology Society
2011
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3208894/ https://ncbi.nlm.nih.gov/pubmed/22027331 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|